GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

131

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Viral evasion of cGAS-STING pathway: opportunities for intervention

Viral evasion of cGAS-STING pathway: opportunities for ...

90

Pseudomonas aeruginosa: persistence beyond antibiotic resistance

Pseudomonas aeruginosa: persistence beyond antibiotic r...

148

The biology of congenital urinary bladder outflow obstruction

The biology of congenital urinary bladder outflow obstr...

53